Elevation Oncology (NASDAQ:ELEV – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Volatility & Risk Elevation Oncology has […]
/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.
/PRNewswire/ Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies.
Elevation Oncology, Inc. announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to. -Today at 07:30 am- MarketScreener
Certain Pre-funded Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023. These Pre-funded Warrants will be under lockup for 61 days starting from 8-JUN-2023 to.